{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AUPH/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T11:30:14.461Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9588,"canonical_name":"Aurinia Pharmaceuticals Inc.","cik":"0001600620","uei":null,"lei":null,"duns":null,"ticker":"AUPH"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":37,"clinical":2},"count":39,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — Aurinia Pharmaceuticals Inc. — 2026-09-11","url_slug":"/sec/cik-0001600620/4/0001600620-26-000068","accession_number":"0001600620-26-000068","importance":30},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Robertson Stephen P.","title":"Chief Legal Officer","shares":11939,"price_per_share":15.95,"usd_value":190427,"security_title":"Common Stock","importance":35.19042705},{"ts":"2026-08-26","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Aurinia Pharmaceuticals Inc. — 2026-08-26","url_slug":"/sec/cik-0001600620/schedule-13d-a/0001104659-26-101785","accession_number":"0001104659-26-101785","importance":70},{"ts":"2026-08-25","kind":"sec.filing","form_type":"4","title":"4 — Aurinia Pharmaceuticals Inc. — 2026-08-25","url_slug":"/sec/cik-0001600620/4/0001837798-26-000013","accession_number":"0001837798-26-000013","importance":30},{"ts":"2026-08-21","kind":"sec.filing","form_type":"144","title":"144 — Aurinia Pharmaceuticals Inc. — 2026-08-21","url_slug":"/sec/cik-0001600620/144/0001837798-26-000010","accession_number":"0001837798-26-000010","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"8-K","title":"8-K — Aurinia Pharmaceuticals Inc. — 2026-08-19","url_slug":"/sec/cik-0001600620/8-k/0001600620-26-000066","accession_number":"0001600620-26-000066","importance":35},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Aurinia Pharmaceuticals Inc. — 2026-08-06","url_slug":"/sec/cik-0001600620/10-q/0001600620-26-000062","accession_number":"0001600620-26-000062","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Aurinia Pharmaceuticals Inc. — 2026-08-06","url_slug":"/sec/cik-0001600620/8-k/0001600620-26-000059","accession_number":"0001600620-26-000059","importance":35},{"ts":"2026-08-03","kind":"clinical.trial","reporter":"Aurinia Pharmaceuticals Inc.","title":"Study of Aritinercept in Patients With Generalized Myasthenia Gravis","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07596901","excerpt":"[\"Myasthenia Gravis, Generalized\"]","importance":45},{"ts":"2026-08-03","kind":"clinical.trial","reporter":"Aurinia Pharmaceuticals Inc.","title":"PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT07611214","excerpt":"[\"Lupus Nephritis\"]","importance":25},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Aurinia Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001600620/4/0001896369-26-000002","accession_number":"0001896369-26-000002","importance":30},{"ts":"2026-06-05","kind":"sec.form144","reporter":"GREGORY KEENAN","title":"Former Affiliate","shares":9593,"usd_value":158490,"security_title":"Common","approx_sale_date":"2026-06-05","accession_number":"0001950047-26-005702","importance":40.031697958},{"ts":"2026-06-05","kind":"sec.filing","form_type":"144","title":"144 — Aurinia Pharmaceuticals Inc. — 2026-06-05","url_slug":"/sec/cik-0001600620/144/0001950047-26-005702","accession_number":"0001950047-26-005702","importance":30},{"ts":"2026-06-04","kind":"sec.form144","reporter":"GREGORY KEENAN","title":"Former Affiliate","shares":25000,"usd_value":408435,"security_title":"Common","approx_sale_date":"2026-06-04","accession_number":"0001950047-26-005622","importance":40.081687},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Aurinia Pharmaceuticals Inc. — 2026-06-04","url_slug":"/sec/cik-0001600620/8-k/0001600620-26-000053","accession_number":"0001600620-26-000053","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"144","title":"144 — Aurinia Pharmaceuticals Inc. — 2026-06-04","url_slug":"/sec/cik-0001600620/144/0001950047-26-005622","accession_number":"0001950047-26-005622","importance":30},{"ts":"2026-06-02","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":206005,"price_per_share":15.28,"usd_value":3147756,"security_title":"Common Shares","importance":53.1477564},{"ts":"2026-06-02","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":206005,"price_per_share":15.28,"usd_value":3147756,"security_title":"Common Shares","importance":53.1477564},{"ts":"2026-06-02","kind":"sec.form144","reporter":"GREGORY KEENAN","title":"Officer","shares":25000,"usd_value":54100000,"security_title":"Common","approx_sale_date":"2026-06-02","accession_number":"0001950047-26-005481","importance":50.82},{"ts":"2026-06-02","kind":"sec.filing","form_type":"144","title":"144 — Aurinia Pharmaceuticals Inc. — 2026-06-02","url_slug":"/sec/cik-0001600620/144/0001950047-26-005481","accession_number":"0001950047-26-005481","importance":30},{"ts":"2026-06-02","kind":"sec.insider.206005","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":206005,"price_per_share":15.28,"usd_value":3147756,"security_title":"Common Shares","importance":18.1477564},{"ts":"2026-06-01","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":343521,"price_per_share":15.28,"usd_value":5249001,"security_title":"Common Shares","importance":55.24900088},{"ts":"2026-06-01","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":343521,"price_per_share":15.28,"usd_value":5249001,"security_title":"Common Shares","importance":55.24900088},{"ts":"2026-06-01","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":99,"price_per_share":15.34,"usd_value":1519,"security_title":"Common Shares","importance":50.00151866},{"ts":"2026-06-01","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":99,"price_per_share":15.34,"usd_value":1519,"security_title":"Common Shares","importance":50.00151866},{"ts":"2026-06-01","kind":"sec.insider.343521","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":343521,"price_per_share":15.28,"usd_value":5249001,"security_title":"Common Shares","importance":20.24900088},{"ts":"2026-06-01","kind":"sec.insider.99","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":99,"price_per_share":15.34,"usd_value":1519,"security_title":"Common Shares","importance":15.00151866},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":262682,"price_per_share":15.31,"usd_value":4021661,"security_title":"Common Shares","importance":54.02166142},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":262682,"price_per_share":15.31,"usd_value":4021661,"security_title":"Common Shares","importance":54.02166142},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":2299,"price_per_share":15.35,"usd_value":35290,"security_title":"Common Shares","importance":50.03528965},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":2299,"price_per_share":15.35,"usd_value":35290,"security_title":"Common Shares","importance":50.03528965},{"ts":"2026-05-29","kind":"sec.insider.262682","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":262682,"price_per_share":15.31,"usd_value":4021661,"security_title":"Common Shares","importance":19.02166142},{"ts":"2026-05-29","kind":"sec.insider.2299","reporter":"TANG KEVIN","title":"Chief Executive Officer","shares":2299,"price_per_share":15.35,"usd_value":35290,"security_title":"Common Shares","importance":15.03528965},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Aurinia Pharmaceuticals Inc. — 2026-05-20","url_slug":"/sec/cik-0001600620/4/0001759910-26-000004","accession_number":"0001759910-26-000004","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Aurinia Pharmaceuticals Inc. — 2026-05-20","url_slug":"/sec/cik-0001600620/4/0001837798-26-000005","accession_number":"0001837798-26-000005","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Aurinia Pharmaceuticals Inc. — 2026-05-20","url_slug":"/sec/cik-0001600620/4/0002126966-26-000003","accession_number":"0002126966-26-000003","importance":30},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Hearne Michael S","title":"Chief Financial Officer","shares":116144,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Robertson Stephen P.","title":"Chief Legal Officer","shares":115541,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Cole Ryan","title":"Chief Operating Officer","shares":116144,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15}]}